Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Epigenetic effects of the natural flavonolignan silibinin on colon adenocarcinoma cells and their derived metastatic cells.

Kauntz H, Bousserouel S, Gossé F, Raul F.

Oncol Lett. 2013 Apr;5(4):1273-1277. Epub 2013 Feb 12.

2.
3.

Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.

Mateen S, Raina K, Jain AK, Agarwal C, Chan D, Agarwal R.

Epigenetics. 2012 Oct;7(10):1161-72. doi: 10.4161/epi.22070. Epub 2012 Sep 10.

4.

Different Schedule-dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.

Hosokawa M, Tanaka S, Ueda K, Iwakawa S.

Biol Pharm Bull. 2017 Sep 28. doi: 10.1248/bpb.b17-00439. [Epub ahead of print]

6.

The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells.

Kauntz H, Bousserouel S, Gossé F, Raul F.

Apoptosis. 2012 Aug;17(8):797-809. doi: 10.1007/s10495-012-0731-4.

PMID:
22555452
7.

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

Zhu WG, Otterson GA.

Curr Med Chem Anticancer Agents. 2003 May;3(3):187-99. Review.

PMID:
12769777
8.

Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived metastatic cells.

Kauntz H, Bousserouel S, Gossé F, Raul F.

Apoptosis. 2011 Oct;16(10):1042-53. doi: 10.1007/s10495-011-0631-z.

PMID:
21779837
9.

Silencing of Wnt5a during colon cancer metastasis involves histone modifications.

Li Q, Chen H.

Epigenetics. 2012 Jun 1;7(6):551-8. doi: 10.4161/epi.20050. Epub 2012 Jun 1.

10.

Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells.

Xu S, Ren J, Chen HB, Wang Y, Liu Q, Zhang R, Jiang SW, Li J.

Curr Pharm Des. 2014;20(11):1881-7.

PMID:
23888960
11.
12.

MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.

Imesch P, Dedes KJ, Furlato M, Fink D, Fedier A.

Int J Oncol. 2009 Sep;35(3):631-40.

13.

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.

Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, Girard L, Martinez ED.

Br J Cancer. 2012 Jan 3;106(1):116-25. doi: 10.1038/bjc.2011.532. Epub 2011 Dec 8.

14.

Dual targeting of epigenetic therapy in cancer.

Hellebrekers DM, Griffioen AW, van Engeland M.

Biochim Biophys Acta. 2007 Jan;1775(1):76-91. Epub 2006 Jul 21. Review.

PMID:
16930846
15.

Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.

Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC Jr.

Cancer. 2011 Oct 1;117(19):4424-38. doi: 10.1002/cncr.26073.

16.

Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells.

Feng W, Cai D, Zhang B, Lou G, Zou X.

Biomed Pharmacother. 2015 Aug;74:257-64. doi: 10.1016/j.biopha.2015.08.017. Epub 2015 Aug 28.

PMID:
26349994
17.

Epigenetic regulation of gene expression as an anticancer drug target.

Ferguson LR, Tatham AL, Lin Z, Denny WA.

Curr Cancer Drug Targets. 2011 Feb;11(2):199-212.

PMID:
21158714
18.

Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNA-methyltransferase 3B.

Liu N, Zhao LJ, Li XP, Wang JL, Chai GL, Wei LH.

Chin Med J (Engl). 2012 Sep;125(18):3273-8.

PMID:
22964322
19.

SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors.

Desai D, Salli U, Vrana KE, Amin S.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):2044-7. doi: 10.1016/j.bmcl.2009.07.068. Epub 2009 Jul 17.

20.

Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells.

Zhou X, Yang XY, Popescu NC.

Biochem Biophys Res Commun. 2012 Apr 6;420(2):325-30. doi: 10.1016/j.bbrc.2012.02.158. Epub 2012 Mar 7.

Supplemental Content

Support Center